340 related articles for article (PubMed ID: 7479201)
1. Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam.
Sullivan MC; Nightingale CH; Quintiliani R; Sweeney KR
Pharmacotherapy; 1995; 15(4):479-86. PubMed ID: 7479201
[TBL] [Abstract][Full Text] [Related]
2. Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam.
Freeman CD; Nightingale CH; Nicolau DP; Belliveau PP; Tessier PR; Fu Q; Xuan DW; Quintiliani R
Pharmacotherapy; 1994; 14(2):185-90. PubMed ID: 8197037
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ampicillin-sulbactam and ticarcillin-clavulanic acid in patients with chronic renal failure: effects of differential pharmacokinetics on serum bactericidal activity.
Hardin TC; Butler SC; Ross S; Wakeford JH; Jorgensen JH
Pharmacotherapy; 1994; 14(2):147-52. PubMed ID: 8197032
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
[TBL] [Abstract][Full Text] [Related]
6. Serum bactericidal activity of ceftriaxone plus metronidazole against common intra-abdominal pathogens.
Freeman CD; Nightingale CH; Nicolau DP; Belliveau PP; Quintiliani R
Am J Hosp Pharm; 1994 Jul; 51(14):1782-7. PubMed ID: 7942906
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.
Sprandel KA; Drusano GL; Hecht DW; Rotschafer JC; Danziger LH; Rodvold KA
Diagn Microbiol Infect Dis; 2006 Aug; 55(4):303-9. PubMed ID: 16887471
[TBL] [Abstract][Full Text] [Related]
8. Comparative activity of cefoxitin, ampicillin/sulbactam, and imipenem against clinical isolates of Escherichia coli and Klebsiella pneumoniae.
Shungu DL; Ponticas S; Gill CJ
Clin Ther; 1989; 11(3):315-8. PubMed ID: 2663161
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
Stratton CW; Weeks LS; Aldridge KE
Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis.
Wasilauskas BL
Diagn Microbiol Infect Dis; 1989; 12(1):39-43. PubMed ID: 2714071
[TBL] [Abstract][Full Text] [Related]
11. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
[TBL] [Abstract][Full Text] [Related]
12. [The effect of a combination of ampicillin and sulbactam against clinical anaerobic isolates].
Werner H; Heizmann W; Heilmann F
Arzneimittelforschung; 1988 Jul; 38(7):866-8. PubMed ID: 3207432
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of pulse dosing versus standard dosing: in vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron.
Ibrahim KH; Gunderson BW; Hermsen ED; Hovde LB; Rotschafer JC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4195-9. PubMed ID: 15504841
[TBL] [Abstract][Full Text] [Related]
14. Single-agent therapy for acute pelvic inflammatory disease: sulbactam/ampicillin versus cefoxitin.
Hemsell DL; Bawdon RE; Hemsell PG; Nobles BJ; Heard MC
J Int Med Res; 1990; 18 Suppl 4():85D-89D. PubMed ID: 2282973
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of antibacterial agents against clinical isolates of Escherichia coli and Klebsiella species from intensive care units.
Gill CJ; Ponticas S; Shungu DL; Guerriero S
Clin Ther; 1991; 13(1):25-37. PubMed ID: 2029725
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of cefoperazone, cefoperazone plus sulbactam, ciprofloxacin, clindamycin, metronidazole, and penicillin G against anaerobic bacteria in an animal model.
Moody JA; Fasching CE; Sinn LM; Gerding DN; Peterson LR
J Lab Clin Med; 1990 Feb; 115(2):190-5. PubMed ID: 1967626
[TBL] [Abstract][Full Text] [Related]
17. A multicentre study to evaluate the effect of sulbactam/ampicillin combination on anaerobic micro-organisms.
Leone F; Morandotti MG; Mazzella P; Sanna A; Ravizzola G; Colombrita D; Pinzi G; Turano R; Menozzi MG; Lecchini R
J Int Med Res; 1990; 18(3):191-200. PubMed ID: 2193834
[TBL] [Abstract][Full Text] [Related]
18. [Comparative in vitro activity of ampicillin, cefoperazone and their combinations with sulbactam, as well as that of other antibiotics against anaerobic organisms].
Rezvan SP; Sidorenko SV; Budanov SV
Antibiot Khimioter; 1995 Apr; 40(4):25-9. PubMed ID: 7654095
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
Brook I
J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
[TBL] [Abstract][Full Text] [Related]
20. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
